Change over period: —
NSE · WANBURY
WANBURY LTD
-49.4% from the 52-week high · +6.8% above the low
Wanbury Ltd. engages in the business of pharmaceutical and related activities, including research. The company is headquartered in Navi Mumbai, Maharashtra. The firm is engaged in the business of pharmaceutical and related activities, including research. The firm operates through two divisions: the Active Pharmaceutical Ingredients (API) Business and the Domestic Formulations Business. The Company, through the Active Pharmaceutical Ingredients (API) Business, provides Metformin and Sertraline. Metformin is used for the treatment for type 2 diabetes and Sertraline is an anti-depressant. The company has approximately 13 API products. The company manufactures Metformin with over 8500 tons per year. Its products include Metformin HCL, Metformin DC/SR, Sertraline, Diphenhydramine, Mefenamic Acid, Glucosamine, Methoxsalen and Paroxetine. The firm's subsidiaries include Wanbury Holdings B. V. (Netherland), Wanbury Global FZE (UAE), Ningxia Wanbury Fine Chemicals Co. Ltd. (China) and Cantabria Pharma S. L. (Spain).
The short version. Promoter holding was 42.98% in Sep 2026, up 3.22 points over 8 quarters.
1 · The price
How has the stock traded?
WANBURY LTD trades 49.4% below its 52-week high and 6.8% above its 52-week low.
2 · The business
Is it growing?
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 183 | 163 | 172 | 133 | 161 | 131 | 139 | 145 |
| Net profit | 9 | 13 | 20 | 1 | 8 | 1 | 34 | 10 |
| Net margin % | 5.0 | 8.3 | 11.8 | 0.9 | 5.0 | 0.8 | 24.1 | 7.1 |
| EPS (₹) | 2.61 | 4.1 | 6.18 | 0.37 | 2.45 | 0.32 | 10.27 | 3.14 |
Annual
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 600 | 576 | 500 | 511 | 393 | 367 | 374 | 374 |
| Net profit | 31 | 56 | -10 | 81 | -13 | 64 | -32 | -32 |
| Net margin % | 5.1 | 9.7 | -2.1 | 15.9 | -3.2 | 17.5 | -8.6 | -8.6 |
| EPS (₹) | 9.32 | 17.09 | -3.18 | 24.94 | -5.04 | 25.79 | -13.49 | -13.49 |
3 · The quality
How well does it turn capital into profit?
.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | — | 51.5 | 200.3 | 31.7 |
| Return on capital % | — | 27.8 | 66.1 | -67.3 |
| EBITDA margin % | — | 13.2 | 17.0 | 4.7 |
| Net margin % | — | 5.1 | 9.7 | -2.1 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | — | — |
| Profit CAGR | — | — |
4 · The owners
Who holds it, and are they adding?
Up 3.22 pts over 8 quarters.
Down 0.13 pts over 8 quarters.
Up 0.02 pts over 8 quarters.
+0 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 39.76 | 39.76 | 39.63 | 43.09 | 43.08 | 43.01 | 43.01 | 42.98 | +3.22 |
| FII | 0.84 | 1.55 | 1.59 | 0.82 | 0.72 | 0.59 | 0.89 | 0.71 | -0.13 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0.06 | 0.02 | +0.02 |
| Public | 59.4 | 58.68 | 58.78 | 56.08 | 56.21 | 56.39 | 56.03 | 56.28 | -3.12 |
Mutual fund holdings · Oct 2026
2 schemes hold this stock
2 the month before.
- Motilal Oswal BSE Healthcare ETF0.02% of NAV
- Bandhan BSE Healthcare Index Fund0.02% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for WANBURY LTD are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about WANBURY LTD
What is the WANBURY LTD share price?
WANBURY LTD (WANBURY) last closed at ₹181.66, up 4.17% on the day. Its 52-week range is ₹163.34 to ₹344.75.
What is the market cap of WANBURY LTD?
WANBURY LTD has a market capitalisation of about ₹608 crore. Its price-to-earnings ratio is 12.3.
How are WANBURY LTD's latest results?
Promoter holding was 42.98% in Sep 2026, up 3.22 points over 8 quarters.
Who owns WANBURY LTD?
As of Sep 2026, shareholding was: Promoter 42.98%, FII 0.71%, DII 0.02%, Public 56.28%.
How many mutual funds hold WANBURY LTD?
2 mutual fund schemes held WANBURY LTD in October 2026. That compares with 2 the month before.
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.